Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 13, 2026

Company name:	SUNCORPORATION
Representative:	Ryusuke Utsumi President & Representative Director
Securities code:	6736 (TSE Standard)
Contact:	Yoshimi Kimura Director
Tel:	+81-52-756-5981

Notice Concerning Revision of Full-year Financial Forecasts

SUNCORPORATION (the "Company") hereby announces that, at a meeting of its Board of Directors held on November 13, 2026, it resolved to revise its consolidated financial forecasts for the fiscal year ending March 31, 2027 (April 1, 2026 to March 31, 2027), which were previously announced on May 15, 2026, in light of recent business performance trends and other factors, as detailed below.

1. Revisions to consolidated financial results forecasts for the fiscal year ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

	Consolidated net sales	Consolidated operating profit	Consolidated ordinary profit	Profit attributable to owners of parent	Consolidated earnings per share
Previously announced forecasts (A)	(Millons of yen) 19,222	(Millons of yen) 2,131	(Millons of yen) 8,300	(Millons of yen) 7,600	(Yen) 353.10
Revised forecasts (B)	12,400	350	2,000	(7,600)	(353.10)
Change (B-A)	(6,822)	(1,781)	(6,300)	(15,200)	—
Change (%)	(35.5)	(83.6)	(75.9)	—	—
(Reference) Actual consolidated results for the previous fiscal year (Fiscal year ended March 31, 2025)	9,907	(15)	5,133	9,663	441.53

2. Reason for the revision

Taking into account the operating environment and business performance trends in the current consolidated fiscal year, the Company has revised its full-year consolidated financial forecasts for the following reasons:

(1) Net Sales and Operating Income:

i. Global Data Intelligence Business: While the number of contracts for forensic and

intelligence solutions has grown steadily, performance is expected to fall short of initial projections due to delays in project deployment schedules and slower-than-expected growth in commercial/private-sector contracts.

ii. Entertainment-Related Business: Performance is projected to fall below initial projections due to sluggish growth in shipment volumes of parts for gaming machines, among other factors.

iii. IT-Related Business: While the impact of the end of 3G service in the previous fiscal year has run its course, and price revisions alongside net sales from EKTech Group (Malaysia) have trended steadily, the launch and expansion pace of the focused IoT cloud brand "OptimaGrid" have been delayed compared to initial expectations.

iv. M&A and Business Alliances: Due diligence and terms negotiations for several M&A transactions that had been expected to contribute to earnings have taken longer than initially anticipated, and their earnings contribution during the current fiscal year is now expected to be limited.

(2) Ordinary Income

i. In addition to the decrease in operating income noted above, the Company reassessed its estimate for share of profit of entities accounted for using equity method regarding its equity-method affiliate, Cellebrite DI Ltd., based on the affiliate's latest business performance trends. As a result, ordinary income is expected to fall below the previous forecast.

(3) Profit attributable to owners of parent

In addition to the significant decrease in ordinary profit, the bottom line is expected to fall substantially below the previous forecast and result in a net loss (factoring in impacts including the recording of gain on change in equity). This is largely due to the recording of ¥12,067 million in income taxes—current, including understatement additional tax, etc., as expenses during the interim period following the receipt of a notice of reassessment (*) based on a tax audit by the Nagoya Regional Taxation Bureau regarding the fiscal year ended March 31, 2025.

The Company has paid ¥9,350 million as stated in the notice of reassessment (comprising corporate tax, local corporate tax, and understatement additional tax; no heavy additional tax was imposed), plus ¥2,645 million in related local taxes and delinquent taxes on national and local taxes, for a total payment of ¥11,996 million.

Having consulted with external experts, the Company believes there is no error in its tax treatment and cannot accept the reassessment disposition by the tax authorities. Accordingly, contesting the decision of the tax authorities, the Company has filed a request for reconsideration with the Nagoya Regional Tax Tribunal in accordance with statutory procedures, seeking the revocation of the reassessment disposition and related penalties.

We kindly ask for the understanding of our shareholders, investors, and market participants regarding the Company's explanation.

*** Note:** As announced in the “Notice Regarding Receipt of Shares of Cellebrite, an Equity-Method Affiliate of the Company” dated November 11, 2024, December 6, 2024, and January 22, 2025, the Company received a total of 10,467,606 shares of Cellebrite DI Ltd. (“Cellebrite”), an equity-method affiliate of the Company, in connection with the consideration adjustment related to Cellebrite’s listing on the NASDAQ Global Select Market.

This is based on the Reverse Triangular Merger Agreement dated April 8, 2021, entered into

among Cellebrite, TWC Tech Holdings II Corp. (the sponsor of the Special Purpose Acquisition Company [SPAC]), and Cupcake Merger Sub, Inc. (a wholly owned subsidiary of Cellebrite), for the purpose of listing Cellebrite on the U.S. NASDAQ Global Select Market on August 31, 2021 (Eastern Standard Time). Under this agreement, as a post-closing consideration adjustment for the transferred shares, if the volume-weighted average price (VWAP) of Cellebrite's shares for 20 trading days out of any 30-trading-day period within five years from the closing date exceeds US12.50, *US*15.00, and US$17.50, respectively, 5,000,000 shares (up to a maximum of 15,000,000 shares) are to be issued for each milestone met to the shareholders at the time of closing, including the Company, in proportion to their shareholding ratios. Furthermore, this consideration adjustment is carried out by Cellebrite free of charge.

With respect to the receipt of these shares, because the shares were to be issued to the shareholders at the time of closing, including the Company, in proportion to their shareholding ratios, the Company recorded the acquisition cost as zero yen in accordance with the relevant provisions of the Corporation Tax Act. However, the Nagoya Regional Taxation Bureau asserts that because the shares were not granted equally in proportion to the number of shares held by each shareholder at the time of share acquisition, the acquisition cost of said shares is the price normally required for their acquisition, and an amount equivalent to said acquisition cost should be included in gross income as a gain from donation.

###